Hauptseite > Publikationsdatenbank > Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0 > print

001     1041313
005     20250414120458.0
024 7 _ |a 10.1007/s00259-024-07038-5
|2 doi
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a 10.34734/FZJ-2025-02212
|2 datacite_doi
024 7 _ |a 39762634
|2 pmid
024 7 _ |a WOS:001390889200001
|2 WOS
037 _ _ |a FZJ-2025-02212
082 _ _ |a 610
100 1 _ |a Verger, Antoine
|0 P:(DE-Juel1)171957
|b 0
|e Corresponding author
245 _ _ |a Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0
260 _ _ |a Heidelberg [u.a.]
|c 2025
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1744283111_2926
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [18F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.Keywords: Brain metastases; Brain metastasis; FDG; FDOPA; FET; Fluciclovine; Metastatic brain tumors; Methionine; PET; Recurrence.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Tolboom, Nelleke
|0 0000-0002-8005-2833
|b 1
700 1 _ |a Cicone, Francesco
|0 0000-0003-4664-1965
|b 2
700 1 _ |a Chang, Susan M.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Furtner, Julia
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 5
|u fzj
700 1 _ |a Gempt, Jens
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Guedj, Eric
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Huang, Raymond Y.
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Johnson, Derek R.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Law, Ian
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Le Rhun, Emilie
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Short, Susan C.
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Bent, M. J. Van den
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Weehaeghe, Donatienne Van
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Vogelbaum, Michael A.
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Wen, Patrick Y.
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Albert, Nathalie L.
|0 0000-0003-0953-7624
|b 17
700 1 _ |a Preusser, Matthias
|0 0000-0003-3541-2315
|b 18
773 _ _ |a 10.1007/s00259-024-07038-5
|g Vol. 52, no. 5, p. 1822 - 1839
|0 PERI:(DE-600)2098375-X
|n 5
|p 1822 - 1839
|t European journal of nuclear medicine and molecular imaging
|v 52
|y 2025
|x 1619-7070
856 4 _ |u https://juser.fz-juelich.de/record/1041313/files/PDF.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1041313
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)171957
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-05
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-05
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-05
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-05
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21